Dr. Reddy’s Shares Slide 6% on Semaglutide Non-Compliance
Dr. Reddy’s Semaglutide and Stock Market Performance: Key Regulatory Setback Dr. Reddy’s Laboratories faced a significant regulatory setback on October 30, 2025, when its shares plummeted 6% following a critical announcement. The pharmaceutical giant received a Notice of Non-Compliance (NON) from Canada’s Pharmaceutical Drugs Directorate regarding its Abbreviated New Drug Submission (ANDS) for Dr. Reddy’s Semaglutide injection. This … Read more
